Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.
Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.
复制标题
DOI：
10.1016/j.fertnstert.2016.09.046
复制
发表时间：
2016-12
影响因子：
6.7
通讯作者：
Nelson, Lawrence M.
中科院分区：
文献类型：
--
作者：
Sullivan, Shannon D.;Sarrel, Philip M.;Nelson, Lawrence M.
关键词：
原发性卵巢功能不全（POI）是一种罕见的，但重要的原因，卵巢激素缺乏症和不孕症的妇女。除了导致不孕症外，POI还与多种健康风险相关，包括令人烦恼的更年期症状，骨密度降低和骨折风险增加，心血管疾病的早期进展，心理影响，可能包括抑郁，焦虑和感知的心理支持减少，认知能力的潜在早期下降和干眼综合征。适当的激素替代治疗，以取代绝经前水平的卵巢性类固醇是至关重要的，以提高生活质量的妇女与POI和改善相关的健康风险。在这篇综述中，我们讨论了POI和与这种疾病相关的并发症，以及安全有效的激素替代治疗方案。为了降低与POI相关的发病率，我们建议使用最接近正常卵巢激素产生的HRT制剂，并持续HRT直至自然绝经的正常年龄，约50岁。我们针对POI女性的特殊人群，包括特纳综合征女性，乳腺癌或卵巢癌风险增加的女性，接近自然绝经年龄的女性和哺乳期女性。
Primary ovarian insufficiency (POI) is a rare but important cause of ovarian hormone deficiency and infertility in women. In addition to causing infertility, POI is associated with multiple health risks, including bothersome menopausal symptoms, decreased bone density and increased risk of fractures, early progression of cardiovascular disease, psychological impact that may include depression, anxiety, and decreased perceived psychosocial support, potential early decline in cognition, and dry eye syndrome. Appropriate hormone replacement therapy to replace premenopausal levels of ovarian sex steroids is paramount to increasing quality of life for women with POI and ameliorating associated health risks. In this review, we discuss POI and complications associated with this disorder, as well as safe and effective hormone replacement therapy options. To decrease morbidity associated with POI, we recommend using HRT formulations that most closely mimic normal ovarian hormone production and continuing HRT until the normal age of natural menopause, ~50 years. We address special populations of women with POI, including women with Turner Syndrome, women with increased risk of breast or ovarian cancer, women approaching the age of natural menopause, and breastfeeding women.
登录
查看更多内容
影响因子：
2.8
作者：
Archer, D. F.
通讯作者：
Archer, D. F.
影响因子：
--
作者：
Braunstein, GD;Sundwall, DA;Watts, NB
通讯作者：
Watts, NB
影响因子：
2.1
作者：
Elias, AN;Pandian, MR;Rojas, FJ
通讯作者：
Rojas, FJ
DOI：
10.1016/s1470-2045(12)70425-4
发表时间：
2012-11
期刊：
The Lancet. Oncology
影响因子：
--
作者：
Collaborative Group on Hormonal Factors in Breast Cancer
通讯作者：
Collaborative Group on Hormonal Factors in Breast Cancer
影响因子：
5.8
作者：
Cartwright, Beth;Robinson, Jillian;Rymer, Janice
通讯作者：
Rymer, Janice